Trevena, Inc.

279 articles about Trevena, Inc.

• Trevena Reports Second Quarter 2023 Results and Provides Business Update

  8/14/2023

  Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today reported its financial results for the second quarter ended June 30, 2023 and provided an overview of its recent operational highlights.

• Trevena, Inc. Appoints Mark Corrigan, M.D. to Board of Directors

  7/20/2023

  Trevena, Inc. announced that Mark Corrigan, M.D. has been appointed to the Company’s Board of Directors, effective July 18 2023.

• Trevena Announces New Topline OLINVYK Data Highlighting Reduced Cost per Admission from ARTEMIS Real-World Outcomes Study

  6/26/2023

  Trevena, Inc., a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system disorders, announced new topline OLINVYK data from the ARTEMIS study.

• Trevena Announces Receipt of Milestone Payment From Partner in China Jiangsu Nhwa Pharmaceutical

  5/31/2023

  Trevena, Inc., a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system disorders, announced that it has received a $3 million milestone payment from its partner in China for the Chinese approval of OLINVYK.

• Trevena Reports First Quarter 2023 Results and Provides Business Update

  5/15/2023

  Trevena, Inc. reported its financial results for the first quarter ended March 31, 2023, and provided an overview of its recent operational highlights.

• Trevena to Release First Quarter 2023 Financial Results on May 15, 2023

  5/9/2023

  Trevena, Inc. announced that it will release its financial results for the first quarter ended March 31, 2023, prior to the market open on Monday, May 15, 2023.

• Trevena Announces Approval of OLINVYK in China

  5/8/2023

  Trevena, Inc.(Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that its partner in China, Jiangsu Nhwa, received formal approval from the National Medical Products Administration for OLINVYK.

• Trevena to Participate in Three Upcoming Conferences

  5/3/2023

  Trevena, Inc., a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system disorders, announced that members of Management will participate in three upcoming conferences.

• Trevena Reports Fourth Quarter 2022 Results and Provides Business Update

  3/30/2023

  Trevena, Inc. reported its financial results for the fourth quarter ended December 31, 2022 and provided an overview of its recent operational highlights.

• Trevena Announces Initial Topline OLINVYK Data from ~200 Patient Real-World Clinical Outcomes Study

  3/30/2023

  Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced initial topline OLINVYK data from two related real-world outcomes studies: VOLITION and ARTEMIS.

• Trevena to Release Fourth Quarter and Full Year 2022 Financial Results on March 30, 2023Company to host a Conference Call & Webcast at 8:00 a.m. ET

  3/27/2023

  Trevena, Inc. today announced that it will release its financial results for the fourth quarter and full year ended December 31, 2022, prior to the market open on Thursday, March 30, 2023.

• Trevena Initiates Targeted Proof-of-Concept Study to Evaluate TRV045 as a Potential Treatment for Epilepsy and Other CNS Disorders

  3/7/2023

  Trevena, Inc.(Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced the initiation of a Phase 1 proof-of-concept study of TRV045, a novel sphingosine-1-phosphate receptor modulator selective for the S1P receptor subtype 1.

• Trevena Announces Publication of OLINVYK Respiratory Physiology Study In ANESTHESIOLOGY

  2/14/2023

  Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced the publication of OLINVYK data in the peer-reviewed journal Anesthesiology.

• Trevena Enrolls First Subject in TRV045 Proof-of-Concept Trial Evaluating S1PR Mechanism of Action and Target Engagement

  1/9/2023

  Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced the enrollment of the first subject in a Phase 1 proof-of-concept study of TRV045, a novel sphingosine-1-phosphate receptor modulator selective for the S1P receptor subtype 1.

• Trevena Announces Poster Presentations of TRV045 Nonclinical Epilepsy Data, and OLINVYK Clinical Neurocognitive and GI Data, at Recent Medical Meetings

  12/8/2022

  Trevena, Inc. today announced that three abstracts related to the Company’s commercial and clinical pipeline were presented at medical meetings in December.

• Trevena Regains Compliance with Nasdaq Listing Requirements - November 29, 2022

  11/29/2022

  Trevena, Inc. announced that it has received notice from the Listing Qualifications Department of the Nasdaq Stock Market LLC by letter dated November 28, 2022 informing Trevena that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550.

• Trevena Reports Third Quarter 2022 Results and Provides Business Update

  11/9/2022

  Trevena, Inc. reported its financial results for the third quarter ended September 30, 2022, and provided an overview of its recent operational highlights.

• Trevena Announces Reverse Stock Split - November 09, 2022

  11/9/2022

  Trevena, Inc. announced that it has filed a Certificate of Amendment to its Certificate of Incorporation to effect a reverse stock split of its common stock at a ratio of 1-for-25.

• Trevena to Release Third Quarter 2022 Financial Results on November 9, 2022Company to host a Conference Call & Webcast at 8:00 a.m. ET

  11/7/2022

  Trevena, Inc. today announced that it will release its financial results for the third quarter ended September 30, 2022, prior to the market open on Wednesday, November 9, 2022.

• Trevena Announces OLINVYK Poster Presentation at the ANESTHESIOLOGY® 2022 Annual Meeting

  10/24/2022

  Trevena, Inc. today announced that an abstract entitled, “A Randomized Double-blind Trial Comparing Oliceridine And Morphine On Ventilation In An Elderly Population” (BOC10) has been accepted for podium presentation in the “Best of Abstracts: Clinical Science” session at the ANESTHESIOLOGY®2022 Annual Meeting, being held October 21-25, 2022 in New Orleans, LA.